CGEM Stock Hub: Cullinan Therapeutics News, T-Cell Engagers and Zipalertinib

CGEM stock at a glance

Where Cullinan Therapeutics stands now

The case has three moving parts: CLN-978 must connect B-cell depletion to repeatable clinical benefit; CLN-049 must turn AML responses into durable remissions; and zipalertinib must translate a regulatory opportunity into Cullinan’s share of U.S. profits. Velinotamig broadens the autoimmune approach toward antibody-producing plasma cells, but its lupus experience remains small: the November 8 update covers 12 treated patients, nine of them evaluable for activity, in an uncontrolled study.

On November 10, 2026 Cullinan reported third-quarter results. Cash, cash equivalents, short- and long-term investments and interest receivable were $313.8 million at September 30, and the company expects its resources to provide runway into 2029 under the current operating plan. Quarterly R&D expense was $40.2 million, G&A $12.4 million and the net loss $49.4 million, against $50.6 million a year earlier; nine-month operating cash use was $127.3 million and no shares were sold under the $200 million ATM through September 30. Cullinan said completion of the first-line zipalertinib NDA submission, initiated by Taiho in October, is expected in November, that CLN-978 multidose data in lupus, rheumatoid arthritis and Sjögren’s disease will be shared in a December webcast, and that it started a potentially registrational Phase 2 study of CLN-049 in relapsed or refractory AML in October and a Phase 1/2 study with venetoclax and azacitidine in newly diagnosed AML in November. Q3 report (Form 8-K, exhibit 99.1) · Form 10-Q

On November 4, 2026 Cullinan announced four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15. According to the company, the CLN-049 abstract from the Phase 1 dose-escalation study in relapsed or refractory AML or MDS reports anti-leukemic activity at the selected Phase 2 target doses of 6 µg/kg and 12 µg/kg and a favorable safety profile for the double step-up dosing regimen; updated results for those regimens will be detailed on the poster on December 13. The other three posters are a trial-in-progress for CLN-049 with azacitidine and venetoclax in newly diagnosed AML, a trial-in-progress for subcutaneous velinotamig in immune thrombocytopenia and warm autoimmune hemolytic anemia, and new preclinical data showing that velinotamig selectively targets BCMA-expressing B-lineage cells that drive autoimmune cytopenias. ASH announcement (Form 8-K, exhibit 99.1)

On November 8, 2026 Cullinan announced velinotamig data from the ongoing Genrix Bio Phase 1b/2a study (NCT07348055) in active, refractory, moderate-to-severe SLE, presented as a poster at ACR Convergence. At the September 8 cutoff, 12 patients had been treated across three multidose cohorts with four intravenous doses on days 1, 4, 8 and 29. Among the first nine patients with at least four weeks of follow-up, eight achieved a SLEDAI-2K reduction of at least four points; of seven with urine protein above 500 mg/24 hours at baseline, five had marked reductions and four reached a complete renal response, with proteinuria below 500 mg/24 hours, within 24 weeks. Anti-dsDNA antibodies and IgG fell, complement C3 improved and CD19-positive B cells were depleted. There were no dose-limiting toxicities, no ICANS and no Grade 3 or higher CRS; Grade 1–2 CRS occurred in two patients, and no Grade 2 events were seen after the step-up dosing was modified. Cullinan holds global rights outside Greater China. Company release

Latest Cullinan Therapeutics news

CGEM stock catalysts: development and reporting dates

• November 8, 2026 — Velinotamig lupus multidose data at ACR: SLEDAI-2K reduction of at least four points in eight of nine evaluable patients; four complete renal responses. Completed Company release · Form 8-K
• November 10, 2026 — Third-quarter 2026 results: $313.8 million of cash, investments and interest receivable at September 30; net loss $49.4 million; runway into 2029 reiterated. Completed Company release
• November 10, 2026 · 2:40 p.m. ET — Fireside chat with CEO Nadim Ahmed and CMO Jeffrey Jones at the Stifel 2026 Healthcare Conference, New York; webcast on the Cullinan investor site. Investor conference Company release (wire copy)
• November 17, 2026 · 9:00 a.m. ET — Fireside chat at the UBS Global Biopharma Conference 2026, London (2:00 p.m. GMT). Investor conference
• November 2026 — Expected completion of Taiho’s first-line zipalertinib NDA submission under Real-Time Oncology Review. Partner regulatory step
• December 12–13, 2026 · ASH Annual Meeting — Four posters: updated CLN-049 Phase 1 dose-escalation data in relapsed or refractory AML and MDS (poster 3385, December 13, 6:00–8:00 p.m.); CLN-049 with venetoclax and azacitidine trial-in-progress (poster 1640, December 12); velinotamig preclinical data in autoimmune cytopenias (poster 2384, December 12) and velinotamig ITP/wAIHA trial-in-progress (poster 3001, December 13). Company-announced posters
• December 2026 — CLN-978 webcast: multidose data from about 20 patients across lupus, rheumatoid arthritis and Sjögren’s disease, longer follow-up of single-target-dose responders and initial Sjögren’s single-target-dose data. Company window
• February 27, 2027 — Zipalertinib monotherapy FDA target. Regulatory target

Velinotamig clinical clearance · First-line submission · ASH posters

Cullinan T-cell engagers: separate evidence packages

CLN-978 is a subcutaneous CD19 × CD3 engager incorporating albumin binding to extend exposure. OUTRACE studies are open-label dose-finding programs rather than controlled efficacy trials. Primary objectives emphasize safety and tolerability; pharmacokinetics, B-cell kinetics and clinical activity help identify future regimens. Trial identifiers are NCT06613360 (SLE) , NCT06994143 (RA) and NCT07041099 (Sjögren’s) .

Velinotamig targets BCMA and CD3. The initial Genrix lupus experience involved two patients who completed four intravenous doses: 3 micrograms/kg followed by three 10-microgram/kg doses. At the May 15 cutoff, SLEDAI scores fell from 16 and 14 to 0 and 2 at week eight; both achieved a complete renal response. Neither had CRS or ICANS in that small observation set. Initial Genrix clinical cases

The November 8, 2026 ACR update extends that experience to 12 treated patients at the September 8 cutoff: eight of nine evaluable patients had a SLEDAI-2K reduction of at least four points, and four of seven with baseline proteinuria above 500 mg/24 hours reached a complete renal response within 24 weeks. The study is open-label and has no control arm.

Zipalertinib applications and contingent economics

FDA accepted the zipalertinib application for advanced EGFR exon-20-insertion NSCLC progressing after platinum chemotherapy, with or without prior amivantamab. The target action date is February 27, 2027. This application is based on the previously treated population, not first-line use. The October 1, 2026 release specifies that it seeks accelerated approval for zipalertinib monotherapy, and that zipalertinib holds Breakthrough Therapy designation in the post-platinum setting. Accelerated approval, if granted, comes with a requirement to confirm clinical benefit in further studies; the specific post-marketing conditions would only be known from the FDA action itself. April 28 acceptance announcement REZILIENT1 is a multicenter phase-1/2 study. Its reported primary efficacy population comprised 176 patients, including 51 previously exposed to amivantamab. Confirmed response was 35.2%, median response duration 8.8 months and median progression-free survival 9.4 months. ORR and duration were assessed by independent central review under RECIST 1.1. The peer-reviewed report includes a broader safety population; the response denominator is not every treated patient. Taiho publication summary · Journal of Clinical Oncology paper

Merlintrader Health Score · $CGEM

Assessed October 2, 2026; reviewed November 8, 2026 after the velinotamig lupus data and November 10, 2026 after the third-quarter results, scores unchanged. Weighted calculation: 4.0×30% + 4.0×30% + 3.0×20% + 3.0×10% + 3.0×10% = 3.60. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

• The first-line zipalertinib NDA submission was still to be completed as of November 10, 2026; the previously treated application has a February 27, 2027 target action date, and neither is an approval.
• A $200 million ATM program remained available with no sales through September 30, 2026, and 161,094 preferred shares, each convertible into ten common shares, were outstanding.
• Autoimmune evidence for CLN-978 and velinotamig comes from small, open-label studies without a control arm; CLN-978’s 45-microgram cohort was stopped after grade-3 cytokine-release syndrome.